Course of radiographic damage over 10 years in a cohort with early rheumatoid arthritis

Lindqvist, Elisabet

doi:10.1136/ard.62.7.611

Cited by 174 publications

(134 citation statements)

References 30 publications

Supporting

Mentioning

109

Contrasting

Unclassified

Order By: Relevance

“…The differences between the group with radiographically stable disease and the group with radiographic progression in terms of ESR, baseline Larsen score, number of DMARDs prescribed, and frequency of MTX use are as would be expected and have a limited impact on the interpretation of our results, which are largely based on the relationship between radiographic progression and the biomarkers measured. In accordance with the results of other studies (21,22), Tables 3 and 4 demonstrate that a wide variety of traditional markers differ between the group with radiographically stable disease and the group with radiographic progression and correlate with changes in the Larsen score.…”

Section: Discussionsupporting

confidence: 90%

Biomarkers predict radiographic progression in early rheumatoid arthritis and perform well compared with traditional markers

Young-Min¹,

Cawston²,

Marshall³

et al. 2007

Arthritis & Rheumatism

110

View full text Add to dashboard Cite

Objective. To evaluate the performance of biochemical and traditional markers in predicting radiographic progression in rheumatoid arthritis (RA).Methods. One hundred thirty-two patients with early RA were treated with nonbiologic therapies for 2 years and studied longitudinally. Genomic DNA was analyzed for presence of the shared epitope. Conclusion. These results indicate that biochemical markers are useful predictors of radiographic progression in RA and that serum MMP-3 levels decrease significantly with MTX therapy. Multivariate models that include MMP-3 and CTX-II perform better than existing traditional markers in predicting radiographic outcome in RA.

show abstract

Section: Discussionsupporting

confidence: 90%

Biomarkers predict radiographic progression in early rheumatoid arthritis and perform well compared with traditional markers

Young-Min¹,

Cawston²,

Marshall³

et al. 2007

Arthritis & Rheumatism

110

View full text Add to dashboard Cite

show abstract

“…However, in seropositive patients, RF was an independent factor for progressive radiographic damage, without any additive or synergistic effects of the presence of DRB1*04 (10,69). Interestingly, in a recent study of patients with early RA, the presence of the SE showed a negative association with radiographic evidence of disease progression (70).…”

Section: Discussionmentioning

confidence: 93%

Association of tumor necrosis factor α polymorphism, but not the shared epitope, with increased radiographic progression in a seropositive rheumatoid arthritis inception cohort

Khanna

Park

et al. 2006

Arthritis & Rheumatism

View full text Add to dashboard Cite

Objective. To determine whether the tumor necrosis factor ␣ (TNFA) -308 guanine-to-adenosine polymorphism and/or the shared epitope (SE) is associated with radiographic damage in patients with early rheumatoid arthritis (RA).Methods. The cohort consisted of 189 patients with early seropositive RA (median 5.6 months since symptom onset) who had active disease, no previous disease-modifying antirheumatic drug treatment, and >2 sets of scored radiographs of the hands/wrists and forefeet. TNFA -308 polymorphism was analyzed by polymerase chain reaction pyrosequencing. The SE was defined as presence of any 1 of the following HLA-DRB1 alleles: *0101, *0102, *0401, *0404, *0405, *0408, *0410, *1001, *1402, or *1406. Radiographic progression was assessed by the total Sharp score.Results. Using a weighted least-squares regression analysis, patients with the -308 TNFA AA plus AG genotypes (n ‫؍‬ 49) had significantly higher rates of progression in erosion scores (median 0.84 versus 0.48 units/year), joint space narrowing (JSN) scores (0.42 versus 0.04), and total Sharp scores (1.70 versus 0.61) compared with patients with the TNFA GG genotype (n ‫؍‬ 140). Presence of the SE (n ‫؍‬ 137) was associated with significantly lower progression rates (per year) for total Sharp scores (median 0.9 versus 1.25 units/year) and JSN scores (0.04 versus 0.41), but not for erosion scores (0.50 versus 0.61) compared with patients without the SE (n ‫؍‬ 52). In a least-squares multiple linear regression model, the presence of the AA plus AG genotypes was associated with a significantly higher progression rate after adjusting for the presence of the SE, interaction between the SE and the AA plus AG genotypes, baseline log C-reactive protein level, Health Assessment Questionnaire Disability Index, total Sharp score, swollen joint count, and presence of osteophytes (osteoarthritis). There was a strong linkage disequili-

show abstract

“…Joint erosion can be seen within 6 months of disease onset in the majority of patients and occurs more rapidly in the first year than in late-stage disease [1]. Historical studies have demonstrated that moderate disability within 2 years of diagnosis is not uncommon, and up to 30 % of patients may be unable to work after 10 years [2].…”

mentioning

confidence: 99%

Rheumatoid arthritis: should we shift the focus from “Treat to Target” to “Treat to Work?”

Almoallim

Kamil

2013

Clin Rheumatol

View full text Add to dashboard Cite

Course of radiographic damage over 10 years in a cohort with early rheumatoid arthritis

Cited by 174 publications

References 30 publications

Biomarkers predict radiographic progression in early rheumatoid arthritis and perform well compared with traditional markers

Biomarkers predict radiographic progression in early rheumatoid arthritis and perform well compared with traditional markers

Association of tumor necrosis factor α polymorphism, but not the shared epitope, with increased radiographic progression in a seropositive rheumatoid arthritis inception cohort

Rheumatoid arthritis: should we shift the focus from “Treat to Target” to “Treat to Work?”

Contact Info

Product

Resources

About